News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
27 May 2026

FEX: Reversing the brain drain

The Future of Export Finance (FEX) network continues to expand its international footprint, with chapters across Finland, the UK, France, the GCC, the Netherlands and DACH...

Perspective
02 June 2026

ECA market mourns untimely loss of industry giant Vineyesh...

The global export credit agency and project finance community is mourning the untimely passing of Vineyesh “Vinny” Sawhney, Senior Vice President of Reliance Industries, who...